Sensorion SA (FRA:RFM)

Market Cap	94.91M -49.7%
Revenue (ttm)	5.65M -12.8%
Net Income	-28.09M
EPS	-0.09
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	20
Average Volume	58
Open	0.2650
Previous Close	0.2650
Day's Range	0.2650 - 0.2650
52-Week Range	0.1210 - 0.5960
Beta	n/a
RSI	44.98
Earnings Date	Mar 16, 2026

About Sensorion

Sensorion SA, a biotechnology company, develops drug candidates for the treatment of inner ear disorders in France. The company’s product portfolio includes SENS-401 SSNHL, which has completed Phase 2b clinical trial for the treatment of Sudden Sensorineural Hearing Loss; SENS-401 CIO that is in Phase 2a clinical trial for the treatment of Cisplatin-Induced Ototoxicity; and SENS-401 Cochlear, which is in Phase 2a clinical which is an orally available small molecule protecting and preserving inner ear tissue from damage, responsible for hearing ...

• Industry: Pharmaceutical Preparations
• Founded: 2009
• Employees: 68
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: RFM

Financial Performance

In 2024, Sensorion's revenue was 6.65 million, an increase of 16.76% compared to the previous year's 5.70 million. Losses were -25.97 million, 17.7% more than in 2023.